Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India

 Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India

Shots:

  • Glenmark has received the DCGI’s approval to initiate P-III FAITH study assessing Favipiravir + Umifenovir + SOC and Favipiravir + SOC in 158 hospitalized patients with moderate COVID-19. On day 1, patients will receive Faviprivir (1800mg, bid) and Umifenovir (800mg, bid), followed by 800mg of each for the remaining course of the treatment
  • Treatment duration of the study is 14days and patients will be discharged after clinical cure & two consecutive negative tests for COVID-19 based on RT-PCR. The two antivirals with different MOA complement and enhance efficacy against COVID-19
  • Additionally, Glenmark is evaluating Favipiravir in P-III clinical study as monothx. with 150 patients with COVID-19 with its anticipated results in Jul/ Aug’2020. Glenmark is the first company to receive DCGI’s approval to conduct clinical trials of Favipiravir against COVID-19 in India

Click here to­ read full press release/ article | Ref: Glenmark | Image: Glenmark

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post